PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
|Articles|April 22, 2014
PEARLITOL® mannitol
Since the 1970's, Roquette has been continuously working on improving the remarkable intrinsic properties by providing mannitol with DC properties, self disintegration, low endotoxin level, leading to the creation of the largest mannitol range for the pharmaceutical industry.
Advertisement
Continuous commitment to Mannitol development to Support the growth of the Pharmaceutical Market Segments
Mannitol has a share of the most desirable qualities that formulators seek in mineral, sugar or even polymeric excipients: notably a characteristic low chemical reactivity, an extraordinarily low level of hygroscopicity making it one of the "driest" products for moisture sensitive formulation, coupled with a pleasant taste and mouthfeel.
Since the 1970’s, Roquette has been continuously working on improving the remarkable intrinsic properties by providing mannitol with DC properties, self disintegration, low endotoxin level, leading to the creation of the largest mannitol range for the pharmaceutical industry: PEARLITOL® C, SD, DC, FLASH and PF.
Company name: ROQUETTE
Website:
E-mail:
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement